Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 415.9 million
Mandate

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 415.9 million

December 15, 2022 Capital Markets and Public M&A Life Sciences & Health

Vinge has advised Hansa Biopharma in connection with a directed share issue through which the company raises proceeds of SEK 415.9 million before transaction costs.

Hansa Biopharma is a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.

Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson, Anders Sundin Lundberg and Petter Hellgren.

Related

Vinge has advised VAROPreem in connection with its acquisition of Sunpine

 Vinge has advised VAROPreem in connection with its acquisition of Sunpine from Sveaskog, Södra Skogsägarna and Lawter.
July 10, 2026

Vinge advises Consolid Equity in connection with the establishment of Petra Group

 Vinge has advised Consolid Equity Investment AB ("Consolid Equity") on the acquisition of Ström & Gulliksson, one of the leading patent agencies in the Nordics. The acquisition forms part of the establishment of Petra Group, a European platform aimed at consolidating patent agencies across Europe to combine expertise and resources primarily within patents and trademarks. Consolid acts as a strategic partner in the new group.
July 08, 2026

Vinge has advised Scandic on new credit facilities with SEK 7.5 billion credit facilities

 Vinge has represented Scandic Hotels Group AB (publ) in connection with a facilities agreement for SEK 7,500,000,000 with a syndicate of banks, arranged by DNB Carnegie Investment Bank AB and Nordea Bank Abp, filial i Sverige.
July 08, 2026